Eric Chen
Founder & Chief Executive Officer Achelois BioPharma
Seminars
Wednesday 18th November 2026
Expanding the Reach of TIL Therapy: Reprogramming Patient Tumor Cells to Generate Potent Antigen-Specific T-Cells for Advanced & Cold Solid Tumors
2:40 pm
- Reprogramming autologous tumor cells into antigen-presenting tumor cells (APTCs) to enable patient-specific antigen presentation without target selection
- Generating polyclonal antigen-specific T cells from peripheral blood to address unresectable and cold solid tumors
- Engineering tumor-specific T cells with intrinsic T-cell modifiers to enhance persistence and overcome tumor-mediated immunosuppression
